Regeneron’s antibody cocktail is the latest COVID-19 drug to ... The first 300 doses will be provided at no cost to patients, although hospitals and clinics may add their own fees.

Scientists from Regeneron selected the two most potent, non-competing virus-neutralising antibodies and scaled up production to create the REGN-COV2 cocktail. REGN-COV2's two antibodies bind ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results topping the market’s revenue expectations , with sales up 10.3% year on year to $3.79 billion. Its non-GAAP profit of $12.07 ...

Elsewhere within Regeneron's product portfolio, Libtayo, a programmed death receptor-1 (PD-1) blocking antibody indicated for non-small cell lung cancer ("NSCLC"), cutaneous squamous cell ...

Regeneron posted Q4 adjusted EPS of $12.07 ... in the company’s share of profits from the commercialization of antibodies, which were $1.043 billion and $886 million in the fourth quarter ...

Leonard Schleifer; Co-Chairman of the Board, President, Chief Executive Officer, Founder; Regeneron Pharmaceuticals Inc George Yancopoulos; Co-Chairman of the Board, President, Chief Scientific ...

Regeneron has started 2025 with an increase in defensive capital allocation - initiation of a dividend and an expanded share buyback program. Increased competitive pressure on the Eylea franchise ...

As for revenue, Regeneron reported it at $3.79 billion for the fourth quarter, which was up 10% year over year. The company's full-year haul came in at $14.2 billion, which was an increase of 8%.

(Reuters) - Regeneron (NASDAQ:REGN) Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and ...

It notched a convincing beat on net income. The quarter saw Regeneron grow its revenue by 10% year over year to just under $3.79 billion. Although non-GAAP (adjusted) net income didn't rise as ...